Research programme: antibody therapeutics - GlaxoSmithKline/GenentechAlternative Names: Antibody therapeutics research programme - GlaxoSmithKline/Genentech
Latest Information Update: 25 May 2007
At a glance
- Originator Genentech; GlaxoSmithKline
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 08 Feb 2005 Early research in Undefined in USA (unspecified route)